Interpretable neural network for risk stratification and drug target discovery based on PBMC transcriptomes

Read full text Summarise with VIRAT
Authors: Ziqing Yu, Liwei Liu, Yugang Zou, Yue Liu, Liming Chen, Lulu Peng, Wei Chen, Jing Wang, Kun Yin, Zhiwei Zhang, Suling Ding, Qinqin Hu
Cited by: 0
References: 52

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Peripheral blood mononuclear cells (PBMCs) play a central role in immune surveillance and disease pathogenesis and provide a minimally invasive source for molecular screening. Here, we developed ME-NET, an intrinsically interpretable deep learning framework for multi-disease screening and risk stratification from PBMC transcriptomic profiles. Using harmonized datasets from heterogeneous clinical backgrounds, ME-NET showed consistent performance and outperformed standard machine-learning baselines. By incorporating curated pathway priors in a pathway-informed layer, ME-NET connects predictions to pathway-level signals and contributing genes, enabling biologically grounded interpretation of disease-associated immune programs. Finally, integrating ME-NET-prioritized targets with drug-gene interaction resources identified candidate compounds for potential therapeutic repurposing. Collectively, these results support the use of interpretable deep learning on blood-derived transcriptomes for scalable multi-disease screening and for prioritizing biomarkers and drug targets.

Fields of Study & Subjects

Bioinformatics and Genomic Networks Computational Drug Discovery Methods Gene expression and cancer classification

Publication details

Journal / source
iScience
Volume
29
Issue
4
Pages
115538–115538
Publication date
30 March 2026
Language
EN